Cited by 12Receptor Mechanisms and SignalingGenetic Associations and EpidemiologyPharmacogenetics and Drug Metabolism

Effects of the β‐agonist, isoprenaline, on the down‐regulation, functional responsiveness and trafficking of β2‐adrenergic receptors with N‐terminal polymorphisms

Open access
Koryakina, Yulia, Jones, Stacie M., Cornett, Lawrence E., Seely, Kathryn, Brents, Lisa, Prather, Paul L., Kofman, Alexander, Kurten, Richard C.·2012·Cell Biology International

Abstract

The β2-AR (β2-adrenergic receptor) is an important target for respiratory and CVD (cardiovascular disease) medications. Clinical studies suggest that N-terminal polymorphisms of β2-AR may act as disease modifiers. We hypothesized that polymorphisms at amino acids 16 and 27 result in differential trafficking and down-regulation of β2-AR variants following β-agonist exposure. The functional consequences of the four possible combinations of these polymorphisms in the human β2-AR (designated β2-AR-RE, β2-AR-GE, β2-AR-RQ and β2-AR-GQ) were studied using site-directed mutagenesis and recombinant expression in HEK-293 cells (human embryonic kidney cells). Ligand-binding assays demonstrated that after 24 h exposure to 1 μM isoprenaline, isoforms with Arg16 (β2-AR-RE and β2-AR-RQ) underwent increased down-regulation compared with isoforms with Gly16 (β2-AR-GE and β2-AR-GQ). Consistent with these differences in down-regulation between isoforms, prolonged isoprenaline treatment resulted in diminished cAMP response to subsequent isoprenaline challenge in β2-AR-RE relative to β2-AR-GE. Confocal microscopy revealed that the receptor isoforms had similar co-localization with the early endosomal marker EEA1 following isoprenaline treatment, suggesting that they had similar patterns of internalization. None of the isoforms exhibited significant co-localization with the recycling endosome marker Rab11 in response to isoprenaline treatment. Furthermore, we found that prolonged isoprenaline treatment led to a higher degree of co-localization of β2-AR-RE with the lysosomal marker LAMP1 (lysosome-associated membrane protein 1) compared with that of β2-AR-GE. Taken together, these results indicate that a mechanism responsible for differential responses of these receptor isoforms to the β-agonist involves differences in the efficiency with which agonist-activated receptors are trafficked to the lysosomes for degradation, or differences in degradation in the lysosomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/cbi20120134

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Isoproterenol predominantly binds β2-ADRs that primarily couple to the Gαs subunit in MEG01 cells and platelets.

    “Isoproterenol (ISO), which predominantly binds to β2-ADRs that primarily couple to the Gαs subunit in both MEG01 cells (Fig. S5G) and in platelets (Fig. S5H) (Koryakina et al., 2012)”

    From A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors (2020) · cites this paper as Koryakina et al., 2012

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Koryakina, Y., Jones, S. M., Cornett, L. E., Seely, K., Brents, L., Prather, P. L., Kofman, A., & Kurten, R. C.
Affiliations
  • Arkansas Children's Hospital (US)
  • University of Arkansas for Medical Sciences (US)
  • University of Virginia (US)
Corresponding author
Koryakina, Yulia
Venue
Cell Biology International
Publisher
Wiley
Published
2012-12
Volume
36
Issue
12
Pages
1171-1183
ISSN
  • 1065-6995 (ISSN-L)
  • 1095-8355
OpenAlex
W2004462370
Cited by
12
References
52
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 1
FWCI
0.51
Type
journal article
Language
en
Open access
Locations
  • Cell Biology International (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Center for Research Resources (2 P20 RR-16460, P20RR016460, S10RR019395, 1 S10 RR 19395)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
beta2-adrenergic receptor, isoproterenol, receptor down-regulation, receptor internalization, receptor trafficking, lysosomal degradation, cAMP signaling, receptor isoforms, disease modifiers
MeSH terms
rab11 GTP-Binding Proteins, Cyclic AMP, Adrenergic beta-Agonists, Humans, Isoproterenol, Polymorphism, Genetic, Down-Regulation, Receptors, Adrenergic, beta-2, Protein Isoforms, rab GTP-Binding Proteins, Protein Transport, Lysosomal-Associated Membrane Protein 1, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review